基于血清蛋白质组分析技术鉴定鼻咽癌ENO1自身抗体诊断分子标志物

国际肿瘤学杂志››2020,Vol. 47››Issue (9): 513-517.doi:10.3760/cma.j.cn371439-20191223-00069

• 论著 •下一篇

基于血清蛋白质组分析技术鉴定鼻咽癌ENO1自身抗体诊断分子标志物

詹晓芬¹, 翁雪芬², 杨时煌³, 许镒洧², 彭裕辉², 郭竑⁴()

¹广东省汕头市中心医院病理科 515000
²汕头大学医学院附属肿瘤医院检验科 515000
³广东省汕头市龙湖区第二人民医院急诊科 515000
⁴汕头大学医学院附属肿瘤医院放疗科 515000

收稿日期:2019-12-23修回日期:2020-03-11出版日期:2020-09-08发布日期:2020-10-27
通讯作者:郭竑 E-mail:38469073@qq.com
基金资助:
广东省自然科学基金(2018A030307079);广东省自然科学基金(2019A151501-1873);汕头市科技计划(汕科府{2017}119号18)

Serum proteomic-based analysis identifying autoantibody against ENO1 as a potential diagnostic biomarker in nasopharyngeal carcinoma

Zhan Xiaofen¹, Weng Xuefen², Yang Shihuang³, Xu Yiwei², Peng Yuhui², Guo Hong⁴()

¹Department of Pathology, Shantou Central Hospital of Guangdong Province, Shantou 515000, China
²Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou 515000, China
³Department of Emergency, Second People's Hospital of Shantou Longhu District of Guangdong Province, Shantou 515000, China
⁴Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515000, China

Received:2019-12-23Revised:2020-03-11Online:2020-09-08Published:2020-10-27
Contact:Guo Hong E-mail:38469073@qq.com
Supported by:
Natural Science Foundation of Guangdong Province(2018A030307079);Natural Science Foundation of Guangdong Province(2019A151501-1873);Shantou Science and Technology Planning Project(2017-119-18)

摘要/Abstract

摘要：

目的筛选鉴定鼻咽癌自身抗体分子诊断标志物。方法应用鼻咽癌CNE2细胞蛋白进行血清蛋白质组分析筛选鼻咽癌潜在的自身抗体分子标志物。于2014年7月至2015年1月在汕头大学医学院附属肿瘤医院选取50例鼻咽癌患者和80例健康体检者,采用酶联免疫吸附试验(ELISA)验证筛选的自身抗体在两组血清中的水平,采用受试者工作特征曲线(ROC)评价诊断效能。结果血清蛋白质组分析结果显示,针对烯醇化酶1(ENO1)的自身抗体在鼻咽癌患者血清中出现阳性反应。ELISA结果显示,鼻咽癌患者血清ENO1自身抗体水平明显高于健康体验者[0.165(0.088,0.378)vs.0.100(0.054,0.117),Z=4.077,P<0.001]。ROC曲线显示,当血清ENO1自身抗体取诊断临界值为0.164时,其诊断鼻咽癌的敏感性为52.0%,特异性为90.0%。在早期鼻咽癌中,ENO1自身抗体阳性率为75.0%。结论血清ENO1自身抗体是鼻咽癌潜在的血清诊断标志物。

关键词:食管肿瘤,早期诊断,自身抗体,血清蛋白质组分析技术,烯醇化酶1

Abstract:

ObjectiveTo screen and identify autoantibody biomarker to diagnose patients with nasopharyngeal carcinoma (NPC).MethodsCandidate autoantibodies against tumor-associated antigens were identified from NPC CNE2 cells using serological proteome analysis. Levels of candidate autoantibody biomarkers were measured by enzyme-linked immunosorbent assay (ELISA) in 50 patients with NPC and 80 normal controls recruited from the Cancer Hospital of Shantou University Medical College between July 2014 and January 2015. Receiver operating characteristic curve (ROC) was employed to evaluate diagnostic efficacy.ResultsSerological proteome analysis showed that sera from patients with NPC yielded a positive spot, of which was identified as enolase 1 (ENO1). ELISA results showed that the level of serum autoantibody against ENO1 in patients with NPC was significantly higher than that in normal controls [0.165 (0.088, 0.378)vs.0.100 (0.054, 0.117),Z=4.077,P<0.001]. With the optimum diagnostic cutoff of 0.164, ROC curve showed the diagnostic sensitivity and specificity of autoantibodies against ENO1 were 52.0% and 90.0%, respectively. Measurement of autoantibody against ENO1 demonstrated a positive rate of 75.0% for early stage NPC.ConclusionAutoantibody against ENO1 may be a potential diagnostic biomarker for NPC.

Key words:Esophageal neoplasms,Early diagnosis,Autoantibody,Serological proteome analysis technique,Enolase 1

詹晓芬, 翁雪芬, 杨时煌, 许镒洧, 彭裕辉, 郭竑. 基于血清蛋白质组分析技术鉴定鼻咽癌ENO1自身抗体诊断分子标志物[J]. 国际肿瘤学杂志, 2020, 47(9): 513-517.

Zhan Xiaofen, Weng Xuefen, Yang Shihuang, Xu Yiwei, Peng Yuhui, Guo Hong. Serum proteomic-based analysis identifying autoantibody against ENO1 as a potential diagnostic biomarker in nasopharyngeal carcinoma[J]. Journal of International Oncology, 2020, 47(9): 513-517.

图/表4

图1

图2

图3

表1

ENO1自身抗体阳性率与50例鼻咽癌患者临床病理特征之间的相关性"

临床病理特征	例数	阳性(%)	χ²值	P值
性别
男	38	21(55.3)	0.675	0.411
女	12	5(41.7)
年龄(岁)
≤50	21	13(61.9)	1.423	0.233
>50	29	13(44.8)
T分期
T_1-2	21	14(66.7)	3.120	0.077
T_3-4	29	12(41.4)
N分期
N_0-1	23	13(64.3)	0.349	0.555
N_2-3	27	13(57.1)
TNM分期
Ⅱ期	8	6(76.2)	1.071	0.301
Ⅲ~Ⅳ期	42	20(47.6)

表1

参考文献18

[1]	Chua MLK, Wee JTS, Hui EP, et al. Nasopharyngeal carcinoma[J]. Lancet, 2016,387(10022):1012-1024. DOI: 10.1016/S0140-6736(15)00055-0. doi:10.1016/S0140-6736(15)00055-0pmid:26321262
[2]	曹新平, 卢泰祥, 叶伟军, 等. Ⅰ、Ⅱ期鼻咽癌外照射加腔内放疗远期疗效的前瞻性研究[J]. 癌症, 2007,26(2):204-207. DOI: 10.3969/j.issn.1000-467X.2007.02.019.
[3]	Chen Y, Sun Y, Liang SB, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage Ⅲ to ⅣB nasopharyngeal carcinoma from endemic regions of China[J]. Cancer, 2013,119(12):2230-2238. DOI: 10.1002/cncr.28049. doi:10.1002/cncr.28049pmid:23576020
[4]	Yip TT, Ngan RK, Fong AH, et al. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma[J]. Oral Oncol, 2014,50(6):527-538. DOI: 10.1016/j.oraloncology.2013.12.011. doi:10.1016/j.oraloncology.2013.12.011
[5]	Lin LH, Xu YW, Huang LS, et al. Serum proteomic?based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma[J]. Clin Proteom, 2017,14:6. DOI: 10.1186/s12014-017-9141-5. doi:10.1186/s12014-017-9141-5
[6]	Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin Ⅰ, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera[J]. J Clin Oncol, 2008,26(31):5060-5066. DOI: 10.1200/JCO.2008.16.2388. doi:10.1200/JCO.2008.16.2388pmid:18794547
[7]	Qin J, Zeng N, Yang T, et al. Diagnostic value of autoantibodies in lung cancer: a systematic review and meta-analysis[J]. Cell Physiol Biochem, 2018,51(6):2631-2646. DOI: 10.1159/000495935. doi:10.1159/000495935pmid:30562746
[8]	Jett JR, Peek LJ, Fredericks L, et al. Audit of the autoantibody test, EarlyCDT-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice[J]. Lung Cancer, 2014,83(1):51-55. DOI: 10.1016/j.lungcan.2013.10.008. doi:10.1016/j.lungcan.2013.10.008
[9]	Sullivan FM, Farmer E, Mair FS, et al. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT-Lung Test (ECLS): study protocol for a randomized controlled trial[J]. BMC Cancer, 2017,17(1):187. DOI: 10.1186/s12885-017-3175-y. doi:10.1186/s12885-017-3175-ypmid:28284200
[10]	Peng YH, Xu YW, Huang LS, et al. Autoantibody signatures combined with Epstein-Barr virus capsid antigen-IgA as a biomarker panel for the detection of nasopharyngeal carcinoma[J]. Cancer Prev Res, 2015,8(8):729-736. DOI: 10.1158/1940-6207.CAPR-14-0397. doi:10.1158/1940-6207.CAPR-14-0397
[11]	Desmetz C, Mange A, Maudelonde T, et al. Autoantibody signatures: progress and perspectives for early cancer detection[J]. J Cell Mol Med, 2011,15(10):2013-2024. DOI: 10.1111/j.1582-4934.2011.01355.x. doi:10.1111/j.1582-4934.2011.01355.x
[12]	Trojanowicz B, Winkler A, Hammje K, et al. Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines[J]. J Mol Endocrinol, 2009,42(3):249-260. DOI: 10.1677/JME-08-0118. doi:10.1677/JME-08-0118pmid:19060179
[13]	Fu QF, Liu Y, Fan Y, et al. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway[J]. J Hematol Oncol, 2015,8(1):22. DOI: 10.1186/s13045-015-0117-5. doi:10.1186/s13045-015-0117-5
[14]	Zhu W, Li H, Yu Y, et al. Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients[J]. Cancer Manag Res, 2018,10:5735-5745. DOI: 10.2147/CMAR.S182183. doi:10.2147/CMAR.S182183pmid:30532594
[15]	Zhang L, Wang H, Dong X. Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer[J]. J Bras Pneumol, 2018,44(1):18-23. DOI: 10.1590/S1806-37562016000000241. doi:10.1590/S1806-37562016000000241pmid:29538538
[16]	程超, 龙孝斌, 李欣, 等. α-烯醇化酶在鼻咽癌中的表达[J]. 临床耳鼻咽喉头颈外科杂志, 2011,25(12):554-556. DOI: 10.3969/j.issn.1001-1781.2011.12.009.
[17]	Liu Z, Chen C, Yang H, et al. Proteomic features of potential tumor suppressor NESG1 in nasopharyngeal carcinoma[J]. Proteomics, 2012,12(22):3416-3425. DOI: 10.1002/pmic.201200146. doi:10.1002/pmic.201200146
[18]	Rucksaken R, Pairojkul C, Pinlaor P, et al. Plasma autoantibodies against heat shock protein 70, enolase 1 and ribonuclease/angiogenin inhibitor 1 as potential biomarkers for cholangiocarcinoma[J]. PLoS One, 2014,9(7):e103259. DOI: 10.1371/journal.pone.0103259. doi:10.1371/journal.pone.0103259pmid:25058392